Evidence map›Paper›PMID 39317662›Full record

ArticleThe Journal of infectious diseases2025

A Transgenic Mouse With a Humanized B-Cell Repertoire Mounts an Antibody Response to Influenza Infection and Vaccination.

Valarmathy Murugaiah, Simon J Watson, Robert F Cunliffe, Nigel J Temperton, Stevo T Reece, Paul Kellam, John S Tregoning

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valarmathy MurugaiahDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Simon J WatsonKymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.ORCID 0000-0002-1741-5742
Robert F CunliffeDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Nigel J TempertonViral Pseudotype Unit, University of Kent and Greenwich, Chatham, United Kingdom.ORCID 0000-0002-7978-3815
Stevo T ReeceKymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.
Paul KellamDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0003-3166-4734
John S TregoningDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0001-8093-8741

Funding

Gates Foundation OPP1159947
6 · The paper itself

Abstract

The development of a universal influenza vaccine likely requires an understanding of previous exposure to influenza virus (through vaccination or infection) and how that shapes the antibody repertoire to vaccination, sometimes called original antigenic sin or antigenic imprinting. While animal models can have a much more defined exposure history, they lack a human B-cell repertoire. Transgenic mice with the complete human immunoglobulin locus enable studies of controlled infection history leading to human-like antibody evolution. Here we evaluated responses to influenza in the Intelliselect transgenic mouse (the Kymouse). We show the Kymouse is susceptible to disease following infection with either H1N1, H3N2, or B/Yamagata influenza viruses and that it induces a robust binding and neutralizing antibody response to all 3 strains of influenza virus. This study demonstrates that human B-cell repertoire mice can be used for influenza virus studies, providing a tool for further interrogation of the antibody response.

Indexed as

Antibodies, ViralB-LymphocytesInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibodies, NeutralizingAntibody FormationDisease Models, AnimalHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusMiceMice, TransgenicVaccinationAntibodies, NeutralizingAntibodies, ViralInfluenza Vaccinesantibodyantigenic sinhumanizedinfluenzauniversal vaccine

Identifiers

PMID39317662
PMCPMC11841647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.